Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical (Nasdaq: OM) reported Q2 2024 financial results, showing mixed performance. Revenue decreased to $27.4 million from $36.0 million in Q2 2023, primarily due to a decline in product revenue. However, recurring revenue from Tablo cartridges and service increased by 24%. The company saw significant improvement in gross margins, with total gross margin rising to 35.7% from 21.4% year-over-year. Operating expenses decreased by 21% to $40.5 million. Net loss narrowed to $34.5 million, or $(0.66) per share. Outset revised its 2024 revenue guidance downward to approximately $110 million, citing lower-than-expected new console placements.
Outset Medical (Nasdaq: OM), a medical technology company focused on reducing dialysis costs and complexity, has announced its plans to release Q2 2024 financial results on Wednesday, August 7, 2024, after market close. The company will host a conference call at 2:00 p.m. Pacific time (5:00 p.m. Eastern time) on the same day to discuss financial and operating results.
The call will be led by Leslie Trigg, Chair and CEO, and Nabeel Ahmed, CFO. Interested participants can register online to receive dial-in numbers and a unique pin. Registration is recommended at least 15 minutes before the call. A live and archived webcast will be available on the company's investor relations website.
Outset Medical (Nasdaq: OM), a medical technology company focused on reducing the cost and complexity of dialysis, will present at the Goldman Sachs 45th Annual Global Healthcare Conference. The presentation is scheduled for June 12, 2024, at 11:20 a.m. Eastern time. A live and archived webcast will be accessible via the 'Investors' section of the Outset Medical website.
Outset Medical, Inc. reported its financial results for the first quarter of 2024, highlighting revenue of $28.2 million, a 12% growth in service and other revenue, and a total gross margin improvement to 29.2%. Operating expenses decreased by 10% from the prior year. The company remains focused on reducing costs, achieving profitability, and capitalizing on the $11 billion U.S. dialysis market opportunity.
Outset Medical, Inc. (Nasdaq: OM) received FDA 510(k) clearance for TabloCart with prefiltration, an accessory for the Tablo Hemodialysis System, improving flexibility for healthcare providers. This innovative technology enhances user experience with versatile prefiltration options and enhanced maneuverability, simplifying dialysis treatment. TabloCart complements Tablo as a single enterprise solution, revolutionizing the dialysis experience for patients and providers.
Outset Medical, a medical technology company (OM), will be presenting at upcoming investor conferences hosted by BofA Securities and RBC Capital Markets in May 2024. The management will discuss the company's innovative dialysis technology to reduce costs and complexity. Webcasts of the sessions will be available on Outset's investor section website.
Summary not available.
Summary not available.
Summary not available.
Summary not available.